Before the huge tariff-delay market rally, the stock was down 35% to about $9 a share. The S&P 500 was 5% higher in that time. A Bernstein analyst has slashed its $9.40 Ford price target to $7.00 ...

One Wall Street veteran is now reevaluating Nvidia's stock price target in light of these developments. Chris Versace, TheStreet Pro Portfolio's lead fund manager, noted that Nvidia is "a likely ...

The decrease in the earnings forecast has consequently led to the lowered price target for Trelleborg’s stock. Following the company’s recent devaluation, the analysts believe that Trelleborg ...

Castillo noted that despite the downgrade in the price target, the adjustment in the stock’s rating reflects a calibration of the market to Caterpillar’s near-term risks and its long-term ...

Furthermore, Target stock trades at a decade-low in terms of price to forward sales, at 0.4X. This is well under the optimum level of less than 2X, with its Zacks Retail-Discount Stores Industry ...

Wall Street firms cut Tesla's stock price target due to tariff impacts on its business. One bank argued Tesla will have little room to raise car prices amid high tariffs. Tesla also faces ...

Netflix, Inc. (NFLX) stock received several price target hikes from sell-side analysts after the streaming giant reported forecast-beating first-quarter results and issued upbeat forward commentary.

On Wednesday, Citi analyst Andrew Coombs revised the price target for London Stock Exchange Group Plc (LON:LSEG:LN) (OTC: LNSTY) to £130.00, down from £135.00, while sustaining a Buy rating on the ...

That's led one analyst to sharply cut his price target on the electric vehicle (EV) leader's stock. Wedbush analyst Dan Ives slashed his price target on Tesla stock from $550 to $315 per share.

Tesla has a mean target price of $306.39, implying 20% upside could be in play. However, the Street-high target of $488 suggests the stock could rally as much as 92% from the current level.

From late 2020 to the summer of 2024, Eli Lilly & Co. (NYSE: LLY) stock was on a tear, up more than 635%. Last year was a transformative year for the Indianapolis-based pharmaceutical giant, with ...

The firm currently has a buy rating on the stock. A number of other research firms also recently issued reports on CRDO. Mizuho dropped their price target on Credo Technology Group from $90.00 to ...